Late-Onset Alcohol Abuse Can Be a Presenting Symptom of Dementia, Researchers Find
Clinicial awareness of connection between alcohol and dementia is paramount to providing the best patient care management
Overall alcohol abuse – classified as when alcohol consumption negatively impacts work or social life or leads to legal ramifications – is present in 1.7 percent of older adults in the United States. Previous research has identified lifelong alcohol abuse as a risk factor for dementia. However, it has been unknown whether older adults who begin abusing acohol late in life have an underlying neurodegenerative disease. Particularly concerning is that people who begin abusing alcohol because of an underlying neurological condition may be misdiagnosed with primary alcohol abuse and referred to traditional addiction treatment programs, a process that may delay correct diagnosis and appropriate behavioral treatment, expend family resources, and add to patient and caregiver burden.
“Our study aimed to identify and compare the frequencies of lifetime alcohol abuse, late-onset alcohol abuse, and alcohol abuse as a first symptom of dementia in a group of patients living with several forms of dementia, including Alzheimer’s disease and frontotemporal dementia,” said Georges Naasan, MD, Associate Professor of Neurology, and Medical Director for the Division of Behavioral Neurology and Neuropsychiatry, at the Icahn School of Medicine at Mount Sinai and senior author of the paper. “What we found is that alcohol abuse may be the first sign of an underlying neurological condition when it presents late in life. In fact, up to 7 percent (nearly 1 in 15) of patients with frontotemporal dementia started abusing alcohol late in life, and 5 percent (1 in 20) did so as the first symptom of the disease. While it is important to identify social factors that may lead to alcohol abuse, such as retirement, loneliness, or loss of income/loved ones/housing, our data should implore health care workers to avoid systematically attributing alcohol abuse to these aspects and prompt clinicians to investigate the possibility of frontal lobe dysfunction.”
The research team conducted a cross-sectional, retrospective study of patients evaluated at an academic referral center between 1999 and 2017 who had a clinical diagnosis of behavioral variant frontotemporal dementia (bvFTD), Alzheimer’s-type dementia, or semantic variant primary progressive aphasia. The presence of alcohol abuse was screened using the National Alzheimer’s Coordinating Center UDS questionnaire completed by clinicians during patient research visits. Lifelong alcohol abuse was defined as alcohol abuse that began before the patient was 40 years old, late-onset alcohol abuse as abuse that began at age 40 or above, and alcohol abuse as a first symptom of dementia as abuse that started within the first three years, either before or after symptom onset.
Among the 1,518 participants screened, late-onset alcohol abuse affected 2.2 percent, higher than the 1.7 percent for older adults overall. The research team found that late-onset alcohol abuse was significantly more frequent in patients with bvFTD than those with Alzheimer’s-type dementia, while there was no difference between the frequency of lifelong alcohol abuse across the three dementia groups. They also found that alcohol abuse as a first symptom occurred in 1.4 percent of all patients, five times more frequently in patients with bvFTD than those with Alzheimer’s-type dementia. The results indicate not only that late-onset alcohol abuse is much more frequent in bvFTD than Alzheimer’s-type dementia, but also the likelihood that the biological mechanisms underlying late-onset and lifelong alcohol abuse are different.
“Because patients who begin using alcohol late in life are usually first seen by psychiatrists, primary care providers, and rehabilitation specialists, these professionals should be aware of the possibility that a neurodegenerative disease might be underlying the onset of alcohol abuse late in life in people who historically didn’t abuse alcohol. Therefore, a specific evaluation including checking for other frontal lobe symptoms should be performed, and patients at risk should be referred to a neurologist,” said Dr. Naasan. “An early and appropriate diagnosis in those patients is paramount for providing the best management, improving patients’ and families’ quality of life, and channeling patients to appropriate care facilities.”
NOTES FOR EDITORS
Full study: “Late-Onset Alcohol Abuse as a Presenting Symptom of Neurodegenerative Diseases” by Elisa de Paula França Resende, Robin Ketelle, Anna Karydas, Isabel Allen, Lea T. Grinberg, Salvatore Spina, William W. Seeley, David C. Perry, Bruce Miller, Georges Naasan (DOI: 10.3233/JAD-215369), published in the Journal of Alzheimer’s Disease, Volume 86, Issue 3 (April 2022). The article is available at: content.iospress.com/articles/journal-of-alzheimers-disease/jad215369.
Funding for this research was provided by the National Inshttps://content.iospress.com/articles/journal-of-alzheimers-disease/jad215369titutes of Health, The National Institute on Aging, and the Larry L. Hillblom Network Grant for the Prevention of Age-Associated Cognitive Decline.
About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. We advance medicine and health through unrivaled education and translational research and discovery to deliver care that is the safest, highest-quality, most accessible and equitable, and the best value of any health system in the nation. The Health System includes approximately 7,300 primary and specialty care physicians; 13 free-standing joint-venture centers; more than 410 ambulatory practices throughout the five boroughs of New York City, Westchester, and Long Island; and more than 30 affiliated community health centers. mountsinai.org
About the Journal of Alzheimer’s Disease
Now in its 24th year of publication, the Journal of Alzheimer’s Disease (JAD) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment, and psychology of Alzheimer’s disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease, and clinical trial outcomes. JAD has a Journal Impact Factor of 4.472 according to Journal Citation Reports (Clarivate, 2020). The journal is published by IOS Press. j-alz.com
About IOS Press
IOS Press is an independent international scientific, technical, medical (STM) publishing house established in 1987 in Amsterdam. We produce around 90 journals and 70 books annually in a broad range of subject categories, primarily specializing in biomedical and life sciences (including neurosciences, medical informatics, cancer research, rehabilitation) and physical sciences (including computer sciences, artificial intelligence, engineering). In addition, we offer specialized services that support scientific advancement. iospress.com